CTOs on the Move


 
NICO gives hope to patients with primary and secondary brain tumors, cysts and hemorrhagic strokes.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

NICO raised $12.5M on 11/19/2018

Similar Companies

Dermavant

A Passion for Science and a Commitment to Dermatology Dermavant Sciences is a specialty biopharmaceutical company developing innovative prescription therapies for dermatologic diseases. Dermavant has acquired promising compounds that address unmet therapeutic needs and has rapidly established a robust dermatology R&D pipeline. We are dedicated to realizing the full potential of biomedical research and to developing and commercializing novel first-in-class or best-in-class therapies that improve patients` lives. The patient is at the heart of everything we do.

MycoWorks

In 2013, co-founders Philip Ross and Sophia Wang formed MycoWorks, a San Francisco-based biomaterials company dedicated to bringing new mycelium-grown materials to the world. MycoWorks` patented Fine Mycelium™ technology, an advanced manufacturing platform and breakthrough in materials science, engineers mycelium during growth to form proprietary, interlocking cellular structures for unparalleled beauty, handfeel, strength and durability. The company`s flagship material- Reishi™ - is a new category of material for the world`s best luxury brands.

Q-Chuck Technologies

Q-Chuck Technologies Inc. is a Edmonton, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Spaltudaq Corporation

Spaltudaq Corporation is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

NuProbe

NuProbe brings together cutting-edge innovations in molecular engineering with leading scientific expertise and management to take on one of the world`s greatest challenges — non-invasive early detection of rare genetic variants in patients. NuProbe will take a multi-platform approach to apply these breakthrough technology capabilities in precision medicine to cancer diagnostics, NIPT, and infectious disease screening, building on scientific findings licensed by Wyss Institute, Harvard University.